| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | David A Montero | Q60976599 |
| P2093 | author name string | Miguel O'Ryan | |
| Roberto Vidal | |||
| Juan Carlos Salazar | |||
| Felipe del Canto | |||
| P2860 | cites work | Bovine innate and adaptive immune responses against Escherichia coli O157:H7 and vaccination strategies to reduce faecal shedding in ruminants | Q38053703 |
| Current trends in detecting non-O157 Shiga toxin-producing Escherichia coli in food. | Q38113584 | ||
| Salmonella infections. | Q38133788 | ||
| Shigella vaccine development: prospective animal models and current status | Q38174128 | ||
| Distribution of classical and nonclassical virulence genes in enterotoxigenic Escherichia coli isolates from Chilean children and tRNA gene screening for putative insertion sites for genomic islands | Q38284901 | ||
| Campylobacter colonization of the chicken induces a proinflammatory response in mucosal tissues | Q38437557 | ||
| Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala | Q38900076 | ||
| Protection against Escherichia coli O157:H7 challenge by immunization of mice with purified Tir proteins | Q38998590 | ||
| Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults | Q39433559 | ||
| Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine | Q39517102 | ||
| Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model | Q39573053 | ||
| Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report). | Q39591612 | ||
| Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine | Q39655324 | ||
| Intragastric immunization of mice with enterohemorrhagic Escherichia coli O157:H7 bacterial ghosts reduces mortality and shedding and induces a Th2-type dominated mixed immune response | Q39862940 | ||
| Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. | Q40460000 | ||
| Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. | Q40469794 | ||
| Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial | Q40501431 | ||
| Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children | Q40552513 | ||
| Campylobacter jejuni in broiler chickens: colonization and humoral immunity following oral vaccination and experimental infection | Q40874632 | ||
| Colonization factors of human enterotoxigenic Escherichia coli (ETEC). | Q41251895 | ||
| Development of a live oral attaching and effacing Escherichia coli vaccine candidate using Vibrio cholerae CVD 103-HgR as antigen vector. | Q41928379 | ||
| A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC. | Q42542793 | ||
| Evidence of direct transmission of Escherichia coli O157:H7 infection between calves and a human | Q43213117 | ||
| Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. | Q43432983 | ||
| Assessment of heterogeneity of efficacy of a three-dose regimen of a type III secreted protein vaccine for reducing STEC O157 in feces of feedlot cattle | Q43452540 | ||
| A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection | Q43461979 | ||
| Immunoprophylactic potential of cloned Shiga toxin 2 B subunit | Q43513677 | ||
| Evaluation of live-attenuated Salmonella vaccines expressing Campylobacter antigens for control of C. jejuni in poultry | Q43649211 | ||
| Attenuated Salmonella enterica serovar Typhimurium lacking the ZnuABC transporter confers immune-based protection against challenge infections in mice | Q43685671 | ||
| Efficacy of Escherichia coli O157:H7 siderophore receptor/porin proteins-based vaccine in feedlot cattle naturally shedding E. coli O157. | Q43706041 | ||
| Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein | Q43867706 | ||
| A two-dose regimen of a vaccine against type III secreted proteins reduced Escherichia coli O157:H7 colonization of the terminal rectum in beef cattle in commercial feedlots | Q43874454 | ||
| Efficacy of a vaccine and a direct-fed microbial against fecal shedding of Escherichia coli O157:H7 in a randomized pen-level field trial of commercial feedlot cattle | Q43881534 | ||
| Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium | Q43982547 | ||
| Comparison of eae, tir, espA and espB genes of bovine and human attaching and effacing Escherichia coli by multiplex polymerase chain reaction | Q44491599 | ||
| In ovo oral vaccination with Campylobacter jejuni establishes early development of intestinal immunity in chickens | Q44754415 | ||
| Fusion expression and immunogenicity of EHEC EspA-Stx2Al protein: implications for the vaccine development | Q44957575 | ||
| Antibiotic susceptibility patterns among Shigella sonnei, isolated during three different periods in Región Metropolitana, Chile | Q45194470 | ||
| Enterohemorrhagic Escherichia coli trivalent recombinant vaccine containing EspA, intimin and Stx2 induces strong humoral immune response and confers protection in mice. | Q46019332 | ||
| Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model | Q46307485 | ||
| Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates | Q46354821 | ||
| Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers. | Q46799503 | ||
| Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine | Q46902186 | ||
| Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine | Q46938617 | ||
| Inoculum size in shigellosis and implications for expected mode of transmission | Q47172816 | ||
| Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter. | Q47823263 | ||
| A mouse model of shigellosis by intraperitoneal infection | Q47887073 | ||
| Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine | Q48026813 | ||
| Characterization of adaptive immune responses induced by a new genetically inactivated Salmonella Enteritidis vaccine | Q49997004 | ||
| Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea | Q24201328 | ||
| Diarrheagenic Escherichia coli | Q24533466 | ||
| Phase and antigenic variation in bacteria | Q24561666 | ||
| Bacterial outer membrane vesicles and vaccine applications | Q24568229 | ||
| The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections | Q24623245 | ||
| Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review | Q26861109 | ||
| Vaccines against invasive Salmonella disease: current status and future directions | Q27007088 | ||
| Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection | Q27026551 | ||
| Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1 | Q28343287 | ||
| Directed evaluation of enterotoxigenic Escherichia coli autotransporter proteins as putative vaccine candidates | Q30155406 | ||
| Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. | Q30369367 | ||
| Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing Anti-STa antibodies | Q30409778 | ||
| Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice. | Q30418998 | ||
| Cloning and characterization of a Campylobacter jejuni 72Dz/92 gene encoding a 30 kDa immunopositive protein, component of the ABC transport system; expression of the gene in avirulent Salmonella typhimurium | Q32185859 | ||
| Use of in vivo-induced antigen technology for identification of Escherichia coli O157:H7 proteins expressed during human infection | Q33214290 | ||
| Molecular basis of antigenic polymorphism of EspA filaments: development of a peptide display technology | Q33215973 | ||
| Association of Escherichia coli O157:H7 tir polymorphisms with human infection | Q33295079 | ||
| Hemolytic uremic syndrome associated to shigatoxin producing Escherichia coli in Chilean children: clinical and epidemiological aspects | Q33383138 | ||
| Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans | Q33395389 | ||
| Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni | Q33396432 | ||
| Humoral immune responses to Shiga-like toxins and Escherichia coli O157 lipopolysaccharide in hemolytic-uremic syndrome patients and healthy subjects | Q33491823 | ||
| Human response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors | Q33598843 | ||
| Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid | Q33607442 | ||
| Detection of intimins alpha, beta, gamma, and delta, four intimin derivatives expressed by attaching and effacing microbial pathogens | Q33658872 | ||
| Pathobiology of salmonella, intestinal microbiota, and the host innate immune response | Q33662126 | ||
| Global burden of Shigella infections: implications for vaccine development and implementation of control strategies | Q33749510 | ||
| Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli | Q33768681 | ||
| Salmonella enterica serovar Typhimurium lacking hfq gene confers protective immunity against murine typhoid | Q33828828 | ||
| Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 | Q33876803 | ||
| Salmonella nomenclature. | Q33907998 | ||
| Enterotoxigenic Escherichia coli elicits immune responses to multiple surface proteins | Q33963134 | ||
| Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel | Q34006223 | ||
| Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia | Q34033376 | ||
| Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium | Q34091652 | ||
| Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously | Q34120919 | ||
| Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults | Q34120926 | ||
| Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. | Q34125990 | ||
| Vero response to a cytotoxin of Escherichia coli | Q34177128 | ||
| Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers | Q34194587 | ||
| Hemorrhagic Colitis Associated with a RareEscherichia coliSerotype | Q34256166 | ||
| Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study | Q34345075 | ||
| Recent advances in understanding enteric pathogenic Escherichia coli. | Q34375210 | ||
| Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity | Q34394744 | ||
| Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children | Q34486402 | ||
| Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection | Q34497115 | ||
| Evaluation of Salmonella enterica serovar Typhimurium TTSS-2 deficient fur mutant as safe live-attenuated vaccine candidate for immunocompromised mice | Q34532843 | ||
| Immunoproteomic analysis to identify Shiga toxin-producing Escherichia coli outer membrane proteins expressed during human infection. | Q34596249 | ||
| Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates. | Q34760675 | ||
| Predicting the public health benefit of vaccinating cattle against Escherichia coli O157 | Q34991352 | ||
| Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. | Q35012362 | ||
| Evaluation of an intragastric challenge model for Shigella dysenteriae 1 in rhesus monkeys (Macaca mulatta) for the pre-clinical assessment of Shigella vaccine formulations | Q37638547 | ||
| Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. | Q37643320 | ||
| Development of an Aotus nancymaae model for Shigella Vaccine immunogenicity and efficacy studies | Q37713347 | ||
| Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7. | Q37713379 | ||
| Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes | Q37720658 | ||
| Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas. | Q37778261 | ||
| A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression | Q37896946 | ||
| A systematic review of vaccinations to reduce the shedding of Escherichia coli O157 in the faeces of domestic ruminants | Q37913560 | ||
| Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates | Q37986492 | ||
| Recent progress toward an enterotoxigenic Escherichia coli vaccine | Q38006998 | ||
| Assessing the existing information on the efficacy of bovine vaccination against Escherichia coli O157:H7--a systematic review and meta-analysis | Q38031556 | ||
| Cross-reactive protection against enterohemorrhagic Escherichia coli infection by enteropathogenic E. coli in a mouse model | Q35075768 | ||
| Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers | Q35159544 | ||
| Current progress in enteropathogenic and enterohemorrhagic Escherichia coli vaccines | Q35193511 | ||
| Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis | Q35272921 | ||
| Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains | Q35273267 | ||
| Enterohemorrhagic Escherichia coli O157:H7 requires intimin to colonize the gnotobiotic pig intestine and to adhere to HEp-2 cells | Q35440445 | ||
| Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier | Q35480510 | ||
| O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative | Q35844488 | ||
| Campylobacter polysaccharide capsules: virulence and vaccines | Q36159521 | ||
| Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea | Q36166749 | ||
| Glycoconjugate vaccine strategies for protection against invasive Salmonella infections | Q36184367 | ||
| Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors | Q36267084 | ||
| Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. | Q36422508 | ||
| Artificial Salmonella Vaccines: Salmonella typhimurium O-Antigen-Specific Oligosaccharide-Protein Conjugates Elicit Protective Antibodies in Rabbits and Mice | Q36446367 | ||
| The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease | Q36505159 | ||
| The EtpA exoprotein of enterotoxigenic Escherichia coli promotes intestinal colonization and is a protective antigen in an experimental model of murine infection | Q36593894 | ||
| Prevalence and trends of aminoglycoside resistance in Shigella worldwide, 1999-2010. | Q36700457 | ||
| Vaccination of chickens against Campylobacter | Q36708484 | ||
| A DNA vaccine against Escherichia coli O157:H7. | Q36777146 | ||
| Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G. | Q36844890 | ||
| Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine | Q36970577 | ||
| An outcomes model to evaluate risks and benefits of Escherichia coli vaccination in beef cattle | Q36974025 | ||
| Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. | Q36989971 | ||
| Recent developments in synthetic oligosaccharide-based bacterial vaccines | Q37090300 | ||
| Attaching and effacing activities of rabbit and human enteropathogenic Escherichia coli in pig and rabbit intestines. | Q37106331 | ||
| Enterotoxigenic Escherichia coli EtpA mediates adhesion between flagella and host cells | Q37106403 | ||
| Characterization of flagella purified from enterohemorrhagic, vero-cytotoxin-producing Escherichia coli serotype O157:H7. | Q37151695 | ||
| A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model | Q37190873 | ||
| Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates | Q37194696 | ||
| Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge | Q37274702 | ||
| Genetic basis of virulence in Shigella species | Q37295263 | ||
| Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli | Q37335500 | ||
| Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine. | Q37335984 | ||
| Campylobacter jejuni: a brief overview on pathogenicity-associated factors and disease-mediating mechanisms | Q37576662 | ||
| Oral immunization with attenuated Salmonella vaccine expressing Escherichia coli O157:H7 intimin gamma triggers both systemic and mucosal humoral immunity in mice. | Q50026293 | ||
| Vaccination of attenuated EIS-producing Salmonella induces protective immunity against enterohemorrhagic Escherichia coli in mice | Q50039335 | ||
| An attenuated Salmonella enterica serovar Typhimurium strain lacking the ZnuABC transporter induces protection in a mouse intestinal model of Salmonella infection | Q50044175 | ||
| The global burden of nontyphoidal Salmonella gastroenteritis | Q50050617 | ||
| Protective ability of subcellular extracts from Salmonella Enteritidis and from a rough isogenic mutant against salmonellosis in mice | Q50093720 | ||
| Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine | Q50183477 | ||
| Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines | Q50425114 | ||
| Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. | Q50854404 | ||
| Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. | Q51745561 | ||
| Use of a siderophore receptor and porin proteins-based vaccine to control the burden of Escherichia coli O157:H7 in feedlot cattle. | Q51794801 | ||
| Variable efficacy of a vaccine and direct-fed microbial for controlling Escherichia coli O157:H7 in feces and on hides of feedlot cattle. | Q54292240 | ||
| Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administe | Q54314338 | ||
| A systemic vaccine based on Escherichia coli O157:H7 bacterial ghosts (BGs) reduces the excretion of E. coli O157:H7 in calves. | Q54339548 | ||
| Escherichia coli O157:H7 shedding in vaccinated beef calves born to cows vaccinated prepartum with Escherichia coli O157:H7 SRP vaccine. | Q54350664 | ||
| Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. | Q54418800 | ||
| Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. | Q54442796 | ||
| Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. | Q54514056 | ||
| A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine. | Q54602080 | ||
| Eimeria species parasites as novel vaccine delivery vectors: Anti-Campylobacter jejuni protective immunity induced by Eimeria tenella-delivered CjaA | Q56892284 | ||
| Development of a new guinea-pig model of shigellosis | Q57099015 | ||
| Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2☆ | Q57563815 | ||
| ESCHERICHIA COLI CYTOTOXIN, HAEMOLYTIC-URAEMIC SYNDROME, AND HAEMORRHAGIC COLITIS | Q57676149 | ||
| Antibody response of patients infected with verocytotoxin-producing Escherichia coli to protein antigens encoded on the LEE locus | Q57819072 | ||
| Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial | Q57926913 | ||
| Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children | Q57940421 | ||
| Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7 | Q59274684 | ||
| Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: Results of a Phase 2, randomized, double-blind placebo-controlled trial | Q59809065 | ||
| Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. | Q64948328 | ||
| Consensus conference statement: Escherichia coli O157:H7 infections--an emerging national health crisis, July 11-13, 1994 | Q72281917 | ||
| Genetic diversity of the Campylobacter genes coding immunodominant proteins | Q73580637 | ||
| Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults | Q74184790 | ||
| Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children | Q77399559 | ||
| Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell/Recombinant B Subunit (WC/rBS) Oral Cholera Vaccine Against Travelers' Diarrhea | Q77552807 | ||
| The specificity of antibody in chickens immunised to reduce intestinal colonisation with Campylobacter jejuni | Q77750674 | ||
| Subcutaneous and intranasal immunization with type III secreted proteins can prevent colonization and shedding of Escherichia coli O157:H7 in mice | Q81296614 | ||
| Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection | Q82754354 | ||
| Subcutaneous and intranasal immunization with Stx2B-Tir-Stx1B-Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice | Q83455297 | ||
| Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers | Q84554549 | ||
| Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine | Q84592118 | ||
| Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge | Q84878018 | ||
| Oral administration of live Shigella vaccine candidates in rhesus monkeys show no evidence of competition for colonization and immunogenicity between different serotypes | Q87281013 | ||
| Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies | Q87419447 | ||
| Changing patterns and widening of antibiotic resistance in Shigella spp. over a decade (2000-2011), Andaman Islands, India | Q87747302 | ||
| Passive immunity with multi-serotype heat-killed Shigellae in neonatal mice | Q88039520 | ||
| P433 | issue | 3 | |
| P921 | main subject | Escherichia coli | Q25419 |
| Campylobacter | Q131488 | ||
| Campylobacter jejuni | Q265488 | ||
| P304 | page(s) | 601-619 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni | |
| P478 | volume | 11 |
| Q37562339 | Chaperone-Usher Pili Loci of Colonization Factor-Negative Human Enterotoxigenic Escherichia coli |
| Q59127826 | Coli Surface Antigen 26 Acts as an Adherence Determinant of Enterotoxigenic and Is Cross-Recognized by Anti-CS20 Antibodies |
| Q39204136 | Corn-based vaccines: current status and prospects. |
| Q90086948 | Evaluations of Alkyl hydroperoxide reductase B cell antigen epitope as a potential epitope vaccine against Campylobacter jejuni |
| Q90482717 | Immunization of mice with chimeric antigens displaying selected epitopes confers protection against intestinal colonization and renal damage caused by Shiga toxin-producing Escherichia coli |
| Q90591990 | Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies |
| Q90024438 | Mixed mucosal-parenteral immunizations with the broadly conserved pathogenic Escherichia coli antigen SslE induce a robust mucosal and systemic immunity without affecting the murine intestinal microbiota |
| Q93033597 | New Promising Targets for Synthetic Omptin-Based Peptide Vaccine against Gram-Negative Pathogens |
| Q37697940 | Ontology-based literature mining of E. coli vaccine-associated gene interaction networks. |
| Q46215190 | Purification and Anti-pathogenic Properties of Immunoglobulin Concentrates from Porcine Blood |
| Q46260190 | Rifaximin fails to prevent campylobacteriosis in the human challenge model: a randomized, double-blind, placebo-controlled trial |
| Q37477196 | Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study. |
| Q39252209 | Surface proteome mining for identification of potential vaccine candidates against Campylobacter jejuni: an in silico approach |
Search more.